A
Ann K. Daly
Researcher at Newcastle University
Publications - 371
Citations - 29792
Ann K. Daly is an academic researcher from Newcastle University. The author has contributed to research in topics: Genotype & Population. The author has an hindex of 87, co-authored 348 publications receiving 26881 citations. Previous affiliations of Ann K. Daly include Royal Victoria Infirmary & University of Geneva.
Papers
More filters
Journal ArticleDOI
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Peter M. Kuehl,Jiong Zhang,Yvonne S. Lin,Jatinder K. Lamba,Mahfoud Assem,John D. Schuetz,Paul B. Watkins,Ann K. Daly,Steven A. Wrighton,Stephen D. Hall,Patrick Maurel,Mary V. Relling,Cynthia Brimer,Kazuto Yasuda,Raman Venkataramanan,Stephen C. Strom,Kenneth E. Thummel,Mark S. Boguski,Erin G. Schuetz +18 more
TL;DR: CYP3A5 was more frequently expressed in livers of African Americans than in those of Caucasians, and may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
Journal ArticleDOI
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
TL;DR: YP2C9 genotyping may identify a subgroup of patients who have difficulty at induction of warfarin therapy and are potentially at a higher risk of bleeding complications.
Journal ArticleDOI
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
Ann K. Daly,Peter T. Donaldson,Pallav Bhatnagar,Yufeng Shen,Itsik Pe'er,Aris Floratos,Mark J. Daly,David Goldstein,Sally John,Matthew R. Nelson,Julia Graham,B. Kevin Park,John F. Dillon,William Bernal,Heather J. Cordell,Munir Pirmohamed,Guruprasad P. Aithal,Christopher P. Day +17 more
TL;DR: Findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.
Journal ArticleDOI
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
Elizabeth Sconce,Tayyaba Khan,Tayyaba Khan,Hilary Wynne,Hilary Wynne,Peter Avery,Peter Avery,Louise Monkhouse,Louise Monkhouse,Barry P. King,Barry P. King,Peter Wood,Peter Wood,Patrick Kesteven,Patrick Kesteven,Ann K. Daly,Ann K. Daly,Farhad Kamali,Farhad Kamali +18 more
TL;DR: The multivariate regression model including the variables of age, CYP2C9 and VKORC1 genotype, and height produced the best model for estimating warfarin dose (R2 = 55%).
Journal Article
Metabolic gene polymorphism frequencies in control populations.
Seymour Garte,Laura Gaspari,A.-K. Alexandrie,Christine B. Ambrosone,Herman Autrup,Judith L. Autrup,H. Baranova,L. Bathum,Simone Benhamou,Paolo Boffetta,C. Bouchardy,K. Breskvar,J. Brockmöller,Ingolf Cascorbi,Margie L. Clapper,Christiane Coutelle,Ann K. Daly,Marco Dell'Omo,Vita Dolzan,C.M. Dresler,Anthony A. Fryer,Aage Haugen,David W. Hein,Allan Hildesheim,Ari Hirvonen,L.L. Hsieh,Magnus Ingelman-Sundberg,Ivan Kalina,Daehee Kang,Masahiro Kihara,Chikako Kiyohara,Pierre Kremers,Philip Lazarus,Loic Le Marchand,Maria Celeste Lechner,E.M.M. van Lieshout,Stephanie J. London,Johannes J. Manni,Christine Maugard,S. Morita,Valle Nazar-Stewart,K. Noda,Yoshio Oda,Fritz F. Parl,Roberta Pastorelli,I. Persson,Wilbert H.M. Peters,Agneta Rannug,Timothy R. Rebbeck,Angela Risch,L. Roelandt,Marjorie Romkes,David Ryberg,Salagovic J,Bernadette Schoket,Janeric Seidegård,Peter G. Shields,Edith Sim,D. Sinnet,Richard C. Strange,Isabelle Stücker,Haruhiko Sugimura,Jordi To-Figueras,Paolo Vineis,M.C. Yu,Emanuela Taioli +65 more
TL;DR: Using the International Project on Genetic Susceptibility to Environmental Carcinogens (GSEC) database containing information on over 15,000 control (noncancer) subjects, the allele and genotype frequencies for many of the more commonly studied metabolic genes in the human population were determined.